Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Persistent varices in cured patients, Understanding the role of hepatic venous pressure gradient

  • Olivas, Pol|||0000-0002-1919-0284
  • Soler-Perromat, Alexandre|||0000-0003-2531-2484
  • Tellez, L.
  • Carrión Rodríguez, José Antonio|||0000-0001-7191-6081
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Ferrusquía-Acosta, José|||0000-0001-8034-1291
  • Lens, Sabela|||0000-0003-4900-411X
  • Guerrero, A.
  • Falgà Tirado, Angeles
  • Vizcarra, Pamela
  • Orts, Lara|||0000-0002-3070-0310
  • Pérez Campuzano, Valeria|||0000-0002-5997-9511
  • Shalaby, Sarah|||0000-0002-8700-6282
  • Torres, Sonia
  • Baiges, Anna|||0000-0002-6963-9203
  • Turon, Fanny|||0000-0001-5940-2838
  • García-Pagán, JC.|||0000-0001-9032-4954
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
Etiologic factor removal (ER) drives recompensation and improves portal hypertension in cirrhosis. Esophageal varices (EV) and portosystemic shunts (PSS) have been found in patients despite hepatic venous pressure gradient (HVPG) dropping below 10 mmHg after ER, questioning HVPG accuracy in reflecting true portal pressure in the setting of ER. We aim to evaluate the correlation of HVPG with direct portal pressure (DPP) in patients with persistence of EV after ER despite HVPG <10 mmHg. Methods: This is a bicentric 'proof of concept' study evaluating HVPG and ultrasound-guided percutaneous DPP in patients with HCV or alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER. Seven patients with HCV and three with alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER were included. At evaluation, all patients had a patent portal vein and were compensated. The median platelet count was 129.5 (IQR 95-145) × 10/ml, and the median liver stiffness measurement was 16.15 (IQR 14.4-22.3) kPa. In five patients, EV remained the same size (two large and three small), and five downsized to small after ER. Wedge hepatic vein pressure (median 19 [IQR 16.5-20] mmHg) and portal pressure (median 18 [IQR 15-19.5] mmHg) had an excellent correlation (R = 0.93, p <0.0001). Portal pressure gradient (PPG) confirmed the absence of clinically significant portal hypertension as identified by HVPG across all the patients. HVPG accurately reflects PPG in the context of HCV and alcohol-related cirrhosis regression. After ER, EV may persist despite HVPG <10 mmHg. The benefit of prophylaxis in patients with EV and HVPG <10 mmHg is unknown. Future studies with clinical endpoints are needed to validate our findings. Despite a favorable evolution after the removal of the etiologic factor, varices persist in some patients, and there is a lack of concise guidelines for the evaluation and management of portal hypertension in this population. Our research underscores the persistence of varices in the absence of clinically significant portal hypertension and significantly demonstrates the accuracy of hepatic venous pressure gradient (HVPG) in reflecting portal vein pressure in this specific patient group. These findings emphasize the crucial role of HVPG in the assessment of portal hypertension after etiologic factor removal and lay the groundwork for further investigation into clinical outcomes and the necessity of non-selective beta-blockers in individuals with persistent varices after the removal of etiologic factor.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases, Observations from a VALDIG multicenter study

  • Pérez Campuzano, Valeria|||0000-0002-5997-9511
  • Rautou, Pierre-Emmanuel|||0000-0001-9567-1859
  • Marjot, Thomas
  • Praktiknjo, Michael|||0000-0001-7033-9956
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Turco, Laura|||0000-0001-8148-3769
  • Ibáñez Samaniego, Luis|||0000-0002-0309-2727
  • González-Alayón, C.|||0000-0003-0215-4874
  • Puente, Ángela
  • Llop, Elba
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Álvarez-Navascués, Carmen
  • Reiberger, Thomas|||0000-0002-4590-3583
  • Verhelst, Xavier|||0000-0002-2798-5415
  • Tellez, Luis
  • Bergmann, JJohanna Birte
  • Orts, Lara|||0000-0002-3070-0310
  • Grassi, Giuseppe
  • Baiges, Anna|||0000-0002-6963-9203
  • Audrey, Payance|||0000-0003-1174-8375
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Villanueva, Càndid|||0000-0002-3674-914X
  • Morelli, Maria Cristina|||0000-0002-9742-1981
  • Murray, Sam
  • Meacham, Georgina|||0000-0003-1929-4152
  • Luetgehetmann, Marc
  • Schulze zur Wiesch, Julian|||0000-0002-5033-1938
  • García-Pagán, JC.|||0000-0001-9032-4954
  • Barnes, Eleanor
  • Plessier, Aurélie|||0000-0001-5656-1622
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients with VLD has not been described and represents the aim of our study. Methods: International, multicenter, prospective observational study in patients with VLD analyzing the incidence of COVID-19 infection after vaccination, severity of side effects, occurrence of thromboembolic events and hepatic decompensation. In a subgroup of patients, the humoral and cellular responses to vaccination were also analyzed. Results: A total of 898 patients from 14 European centers - part of the VALDIG network - were included, 872 (97.1%) patients received two vaccine doses (fully vaccinated), and 674 (75.1%) three doses. Of the total cohort, 151/898 had a COVID-19 infection prior to vaccination, of whom 9/151 (5.9%) were re-infected. Of the 747/898 patients who were not previously infected, 11.2% (84/747) were diagnosed with a COVID-19 infection during the study period. Two infected patients required intensive care unit admission and infection was fatal in two fully vaccinated patients. Adverse effects were reported in around 40% of patients, with local side effects being the most frequent. During the study period, 31 (3.5%) patients had thromboembolic events and 21 (2.3%) hepatic decompensations. No cases of vaccine-induced thrombocytopenia were reported. Vaccine immunogenicity was assessed in 36 patients; seroconversion reached 100% and IFNy T-cell responses significantly increased post two mRNA-1273 vaccine doses. Conclusion: Patients with VLD seem to have a preserved immune response to SARS-CoV-2 vaccination, which appears to be safe and effective in preventing severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, though the contribution of vaccination as a cofactor in VLD remains to be elucidated. Impact and implications: Patients with vascular liver disease (VLD) are at increased risk of both SARS-CoV-2 infection and severe COVID-19 disease. The potential risks associated with vaccination against this infection need thorough investigation. Our research enhances the understanding of the effects of COVID-19 vaccination in patients with VLD, highlighting its good tolerability. Moreover, patients with VLD appear to have a preserved immune response to SARS-CoV-2 vaccination, providing protection against severe COVID-19 infection. Our study cannot definitively establish a direct link between vaccination and thrombotic events, and no cases of vaccine-induced thrombocytopenia were reported.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension, a randomized, single-blind clinical trial

  • Pérez Campuzano, Valeria|||0000-0002-5997-9511
  • Olivas, Pol|||0000-0002-1919-0284
  • Ferrusquía-Acosta, José|||0000-0001-8034-1291
  • Torres, Sonia
  • Borràs, Roger|||0000-0002-8585-2522
  • Baiges, Anna|||0000-0002-6963-9203
  • Orts, Lara|||0000-0002-3070-0310
  • Vizcarra, Pamela
  • Falgà Tirado, Angeles
  • Codina, Joana|||0000-0002-1768-9460
  • Shalaby, Sarah|||0000-0002-8700-6282
  • Ojeda, Asunción
  • Turon, Fanny|||0000-0001-5940-2838
  • Hernández-Gea, Virginia|||0000-0001-7937-984X
  • Cárdenas, Andrés|||0000-0002-0764-7873
  • García-Pagán, JC.|||0000-0001-9032-4954
Background & Aims: Continuous infusion of terlipressin may result in a more sustained reduction in portal pressure with fewer adverse effects than administered as a bolus. This study aimed to compare the hepatic and cardiopulmonary hemodynamic effects and safety profiles of bolus vs. terlipressin continuous infusion. Methods: This is a single-center, single-blinded, double-dummy, parallel-group, clinical trial in which 38 patients with cirrhosis and portal hypertension were randomized to receive the following: 1 mg bolus of terlipressin + continuous infusion of placebo (TERLBOL, n = 12), a bolus of placebo + continuous infusion of terlipressin (2 or 4 mg/day if <10% reduction in hepatic venous pressure gradient [HVPG] at 30 min of infusion) (TERLINF, n = 14), or a bolus of octreotide (50 μg) + continuous infusion of octreotide (50 μg/h) (OCTR, n = 12) as an additional control group. HVPG, cardiopulmonary pressures, and cardiac output were measured at baseline and after 30, 60, and 120 min. Results: Sixty-eight percent of patients were male, with a median age of 59 years. There were no significant differences in baseline characteristics. In the TERLBOL group, there was a nonsignificant reduction in HVPG (at 120 min, -4.9%; p = 0.14). However, cardiopulmonary and mean arterial pressures significantly increased, whereas cardiac output and heart rate significantly decreased. In the TERLINF group, there were nonsignificant changes in cardiopulmonary hemodynamics or HVPG (NS) despite doubling the infusion dose after 30 min in 13/14 patients. In the OCTR group, there was a nonsignificant reduction in HVPG (at 120 min, -4.9%; p = 0.08), and pulmonary capillary pressure significantly decreased. All treatments were well tolerated, and no adverse events were observed. Conclusions: There were nonsignificant reductions in HVPG with the three therapeutic strategies. Further investigations are warranted to determine the optimal dosing strategy for continuous infusion of terlipressin in patients with cirrhosis and portal hypertension. Impact and implications: The results of our study do not show a significant reduction in portal pressure, at least in the first 2 h after the selected dose. Although the study was not performed in the setting of acute variceal bleeding and terlipressin was used as a standard therapy, these results do not support the treatment strategy of terlipressin infusion alone at the doses studied for the management of acute variceal bleeding, where a quick reduction in portal pressure is thought to play a major role controlling variceal bleeding. It is important to highlight that the continuously infused terlipressin regimen is better tolerated and appears to have a better cardiopulmonary safety profile. Other treatment strategies of continuous terlipressin infusion, such as initial bolus administration or higher infusion doses, should be evaluated to support its use in managing variceal bleeding. Clinical trial identifier: EudraCT No. 2019-004328-39.